Correlation Engine 2.0
Clear Search sequence regions


  • adult (2)
  • cancer (19)
  • humans (1)
  • institutes (1)
  • signals (1)
  • Sizes of these terms reflect their relevance to your search.

    The early detection of cancer is a key goal of the National Cancer Plan formally released by the National Institutes of Health's (NIH) National Cancer Institute (NCI) in April 2023. To support this effort, many laboratories and vendors are developing multi-cancer detection (MCD) assays that interrogate blood and other bodily fluids for cancer-related biomarkers, most commonly circulating tumor DNA (ctDNA). While this approach holds promise for non-invasively detecting early signals of multiple different cancers and potentially reducing cancer-related mortality, there is a dearth of prospective clinical data to inform the deployment of MCD assays for cancer screening in the general adult population. In this review we highlight differing technologies that underpin various MCD assays in clinical development, the importance of achieving adequate performance specifications for MCD assays, ongoing clinical studies investigating the utility of MCD assays in cancer screening and detection, and efforts by the NCI's Division of Cancer Prevention (DCP) to establish a network infrastructure that has the capacity to comprehensively address the scientific and logistical challenges of evaluating blood-based MCD approaches and other cancer screening tools. Published by Elsevier Inc.

    Citation

    Maria Farooq, Elyse Leevan, Jibran Ahmed, Brian Ko, Sarah Shin, Andre De Souza, Naoko Takebe. Blood-based multi-cancer detection: A state-of-the-art update. Current problems in cancer. 2024 Feb;48:101059

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38181630

    View Full Text